TY  - BOOK
AU  - Haggerty,Samantha
ED  - Nova Biomedical (Publishing company).
TI  - Bladder cancer: risk factors, emerging treatment strategies and challenges 
T2  - Cancer etiology, diagnosis and treatments
SN  - 9781633216662
PY  - 2014///
CY  - New York
PB  - Nova Biomedical
KW  - Urinary Bladder Neoplasms
N1  - Includes bibliographical references and index; Cancer stem cell (CSC) in bladder malignancy; Jianmin Zhang; (and two others) --; The five senses in bladder cancer diagnostics; Caterina Gulia; (and four others) --; Bladder cancer in pediatric patients; Santiago Vallasciani; (and four others) --; Multi-tasking chemoinformatic model for the efficient discovery of potent and safer anti-bladder cancer agents; Alejandro Speck-Planche and M. N. D. S. Cordeiro --; Long non coding mitochondrial RNAs as potential targets for diagnosis and therapy of bladder cancer; Jamie Villegas; (and ten others) --; Histological variants of urothelial carcinoma; Hyung Suk Kin and Ja Hyeon Ku --; Novel therapeutic modalities in patients with advanced or metastatic urothelial carcinoma; Kazumasa Matsumoto; (and four others)
N2  - Bladder cancer is the fifth most common form of cancer worldwide and is mainly prevalent in developed countries. It is thought to arise through two distinct pathways: the noninvasive and the invasive. The noninvasive pathway gives rise to a superficial papillary carcinoma that is characterized by activating mutations in oncogenes such as H-ras, FGFR3 and PI3K. This pathway is rarely lethal as superficial papillary carcinomas can be readily removed through transurethral resection. However, 15% of noninvasive urothelial tumors can transform into invasive carcinomas and have high recurrence 80%.--
ER  -